aTyr Pharma
ATYR
47 hedge funds and large institutions have $154M invested in aTyr Pharma in 2021 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 10 increasing their positions, 12 reducing their positions, and 11 closing their positions.
55% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 11
12% more funds holding
Funds holding: 42 → 47 (+5)
1.89% more ownership
Funds ownership: 72.07% → 73.97% (+1.9%)
7% less call options, than puts
Call options by funds: $656K | Put options by funds: $703K
11% less capital invested
Capital invested by funds: $172M → $154M (-$18.6M)
17% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 12
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TM
Tikvah Management
Charlotte,
North Carolina
|
+$10.2M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$1.73M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.72M |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$960K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$879K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$4.4M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$3.45M |
| 3 |
VF
Virtu Financial
New York
|
-$1.3M |
| 4 |
Jane Street
New York
|
-$1.14M |
| 5 |
Two Sigma Advisers
New York
|
-$794K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
T. Rowe Price Associates
Baltimore,
Maryland
| – | -$109K | -12,024 | Closed |
|
|
SBIA
52
Sheaff Brock Investment Advisors
Indianapolis,
Indiana
| – | -$100K | -11,000 | Closed |
|
53
Group One Trading
Chicago,
Illinois
| – | -$16.9K | -2,022 | Closed |
|
|
TRCT
54
Tower Research Capital (TRC)
New York
| – | -$5.47K | -656 | -96% |
|
55
Bank of America
Charlotte,
North Carolina
| – | -$3K | -382 | Closed |
|
|
CHA
56
Carmichael Hill & Associates
Gaithersburg,
Maryland
| – | -$3K | -300 | Closed |
|
ATYR Hedge Fund Activity: Q4 2021 in Review
47 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in aTyr Pharma (ATYR) for Q4 2021, worth a combined $154M — down 11% from $172M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new ATYR positions and 11 closed out — a net gain of 6 holders — while 10 added to existing stakes and 12 trimmed.
The largest buyer was Tikvah Management, opening a new position worth an estimated $10.2M. The largest seller was Ikarian Capital, cutting an estimated $4.4M.
- 47 institutional investors held aTyr Pharma (ATYR) as of Q4 2021, up from 42 in Q3 2021.
- Funds reported $154M of aTyr Pharma stock for Q4 2021, down 11% quarter-over-quarter.
- 17 funds opened new aTyr Pharma positions in Q4 2021 and 11 closed out, a net change of +6 holders.
- The largest aTyr Pharma buyer in Q4 2021 was Tikvah Management, an estimated $10.2M added.
- The largest aTyr Pharma seller in Q4 2021 was Ikarian Capital, an estimated $4.4M sold.
Based on aggregated 13F filings for Q4 2021.